No stem cell therapy for menopause has received FDA approval. The US agency has issued guidance statements warning that unapproved cellular therapies marketed for menopausal symptoms lack adequate safety or efficacy evidence. Most treatments offered internationally are not subject to formal regulatory clearance for this indication, operating instead under various national regulatory frameworks or as research protocols.
The menopausal transition involves profound shifts in oestrogen and progesterone levels, triggering vasomotor symptoms such as hot flushes and night sweats, alongside mood changes, sleep disruption, and vaginal dryness. Whilst conventional hormone replacement therapy addresses many symptoms, some women seek or require alternatives. Regenerative medicine approaches—particularly placental-derived exosomes and mesenchymal stem cells—are being studied as potential supplements to traditional management, with interest centred on whether these agents might support natural hormonal regulation and tissue repair. Current research remains exploratory, focused on mechanisms rather than clinical equivalence to established treatments.
Am I a candidate? → · Menopause & Hormonal Health: full overview → · Menopause & Hormonal Health cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Dr Dmytro Stoyanov (Urologist · 31+ yrs clinical practice) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
GMP-zertifizierte regenerative Medizin mitten in der EU — ab 3.000–8.000 €, ein Bruchteil der US- oder Deutschland-Preise. Individuelle Protokolle für internationale Patienten aus über 50 Ländern.
Kostenlose ärztliche Prüfung